Literature DB >> 2550868

The risk of enucleation after proton beam irradiation of uveal melanoma.

K M Egan1, E S Gragoudas, J M Seddon, R J Glynn, J E Munzenreider, M Goitein, L Verhey, M Urie, A Koehler.   

Abstract

Enucleation after proton beam irradiation of uveal melanomas occurred in 64 (6.4%) of 994 eyes with a median follow-up time of 2.7 years. The median time between irradiation and enucleation in the 64 enucleated eyes was 13 months. The probability of retaining the eye was 95 and 90%, 2 and 5 years postirradiation, respectively. Three percent of eyes were enucleated during posttreatment year 1, and the yearly rate was 1% by the fourth year. No patient had enucleation later than 5 1/2 years posttreatment. The complication most likely to result in enucleation was neovascular glaucoma although this was frequently managed without enucleation. Other common reasons for enucleation were documented or suspected tumor growth and complete retinal detachment with associated loss of vision. The leading risk factors for enucleation were anterior tumor margin involving the ciliary body, tumor height greater than 8 mm, and proximity of the tumor to the fovea. Based on the presence or absence of these factors, 5-year eye retention rates were 99, 92, and 76% for low-, moderate-, and high-risk groups, respectively. Thus, the probability of eye retention after proton beam irradiation is high even among those at greatest risk of enucleation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2550868     DOI: 10.1016/s0161-6420(89)32738-2

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  18 in total

1.  A randomized, controlled trial of varying radiation doses in the treatment of choroidal melanoma.

Authors:  E S Gragoudas
Journal:  Trans Am Ophthalmol Soc       Date:  1998

2.  Where is the superiority of proton radiation for ocular tumours?

Authors:  Nikolaos E Bechrakis; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-07       Impact factor: 3.117

3.  Experimental study on the fractionation schedule for proton irradiation of uveal melanoma.

Authors:  G Wollensak; L Zografos; C Perret; E Egger; H Fritz-Niggli
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

4.  Proton therapy for uveal melanomas and other eye lesions.

Authors:  J E Munzenrider
Journal:  Strahlenther Onkol       Date:  1999-06       Impact factor: 3.621

5.  Endodrainage, Tumor Photocoagulation, and Silicone Oil Tamponade for Primary Exudative Retinal Detachment due to Choroidal Melanoma Persisting after Proton Beam Therapy.

Authors:  Ira Seibel; Dino Cordini; Gregor Willerding; Aline Isabel Riechardt; Antonia Maria Joussen
Journal:  Ocul Oncol Pathol       Date:  2014-07-22

6.  Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study.

Authors:  Anne Sudaka; Antoine Susini; Cristiana Lo Nigro; Jean-Louis Fischel; Nicolas Toussan; Patricia Formento; Federica Tonissi; Laura Lattanzio; Elvio Russi; Marie-Christine Etienne-Grimaldi; Marco Merlano; Gérard Milano
Journal:  Invest New Drugs       Date:  2012-06-20       Impact factor: 3.850

7.  Concurrent versus sequential application of ferromagnetic hyperthermia and 125I brachytherapy of melanoma in an animal model.

Authors:  W F Mieler
Journal:  Trans Am Ophthalmol Soc       Date:  1997

8.  Long-term follow-up after uveal melanoma charged particle therapy.

Authors:  D H Char; S M Kroll; J Castro
Journal:  Trans Am Ophthalmol Soc       Date:  1997

9.  Proton beam radiotherapy in the management of uveal melanoma: Clinical experience in Scotland.

Authors:  Samir Aziz; Alex Taylor; Andrzej McConnachie; Alex Kacperek; Ewan Kemp
Journal:  Clin Ophthalmol       Date:  2009-06-02

Review 10.  The effectiveness and safety of proton radiation therapy for indications of the eye : a systematic review.

Authors:  Geertruida E Bekkering; Anne W S Rutjes; Vasiliy V Vlassov; Daniel M Aebersold; Konrade von Bremen; Peter Jüni; Jos Kleijnen
Journal:  Strahlenther Onkol       Date:  2009-04-16       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.